Vivelle-dot
NDC Package 0078-0344-45

The code 0078-0344-45 identifies a specific commercial package of 3 box in 1 carton / 8 pouch in 1 box / 1 patch in 1 pouch / 3.5 d in 1 patch of Vivelle-dot, labeled by Novartis Pharmaceuticals Corporation. This is formulated for use and contains as the active substance.

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on January 08, 1999. The current certification is valid through May 31, 2025.

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078034445. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.